Current funding opportunities related to TB and HIV, expired RFAs will be hidden after closing date. Sort using the tags menu to the right.
For funding opportunities related to global health, please see the Vanderbilt Institute for Global Health announcements found here.
Understanding the Role of the M. Tuberculosis Granuloma in Tuberculosis (TB) Disease and Treatment Outcomes (R01 Clinical Trial Not Allowed), expires 02/23/2021
Application Due Date(s): February 22, 2021, All applications are due by 5:00 PM local time of applicant organization.
To support research to better define the role of the granuloma, the hallmark structure of pulmonary tuberculosis (TB), in TB disease and disease outcomes. Improved understanding of the granuloma will provide a much-needed knowledge base for the development of improved therapeutic approaches.
https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-20-057.html
Notice of Special Interest (NOSI): Mechanisms of Mycobacterial-Induced Immunity in HIV-Infected and/or Uninfected Individuals to Inform Innovative Tuberculosis Vaccine Design
The purpose of this Notice of Special Interest (NOSI) is to stimulate innovative studies to identify and understand the immune responses that mediate protection fromMycobacterium tuberculosis(Mtb) infection or progression to active tuberculosis (TB) disease. Studies may focus on any stage of mycobacterial infection or following vaccination with Bacillus Calmette-Guérin (BCG) or investigational TB vaccines and may include HIV-infected or uninfected individuals.
Research supported under this NOSI should go beyond descriptive information currently known about Mtb infection, immune responses to TB vaccines, or immune modulation by non-tuberculous mycobacterial (NTM) infection, or by HIV/AIDS. Applications that include characterization of the timing, anatomical location, and contribution to disease outcome, of mucosal and/or systemic immune responses to mycobacterial infection and/or vaccination are sought. This research is expected to advance understanding of immune mechanisms in Mtb infection/vaccination and contribute to the advancement of new TB vaccines, including in populations also infected with HIV.
NIAID June 2020 Council-Approved Concepts, DMID
Concepts represent early planning stages for program announcements, requests for applications, notices of special interest, or solicitations for Council's input.
Request for Applications—proposed FY 2022 initiative
Understanding the Role of the M. Tuberculosis Granuloma in Tuberculosis (TB) Disease and Treatment Outcomes
Objective: To support research to better define the role of the granuloma, the hallmark structure of pulmonary tuberculosis (TB), in TB disease and disease outcomes. Improved understanding of the granuloma will provide a much-needed knowledge base for developing improved drugs, including host-directed therapies.
Contact: Karen Lacourciere
Tuberculosis Research Advancement Centers (TRACs)
Objective: To foster, support, and elevate multidisciplinary tuberculosis (TB) research and provide exceptional mentorship to early-career investigators at institutions with a concentration of TB researchers and a minimum TB funded research base (FRB).
Contact: Lakshmi Ramachandra
You can find more information in: https://www.niaid.nih.gov/grants-contracts/
Global Infectious Disease Research Training Program (D43 Clinical Trial Optional), expires: 08/04/2022
Purpose: this Funding Opportunity Announcement (FOA) encourages joint applications for the Global Infectious Disease (GID) Research Training programs from U.S. and low- and middle-income country (LMIC) institutions. The application should propose a collaborative training program that will strengthen the capacity of a LMIC institution to conduct infectious disease research not including HIV/AIDS. FIC will support research-training programs that focus on major endemic or life-threatening emerging infectious diseases, neglected tropical diseases, infections that frequently occur as co-infections in HIV infected individuals or infections associated with non-communicable disease conditions of public health importance in LMICs. Training related to prevention, treatment or public health approaches to any technical area of basic, epidemiology, clinical, behavioral or social science health research may be supported. Research Training programs should incorporate didactic, mentored research and professional development skills components to prepare individuals for careers that will have significant impact on the priority health research needs of LMICs.
This Funding Opportunity Announcement (FOA) allows support of trainees as the lead investigator of an independent clinical trial; or a separate ancillary clinical trial or proposing to gain research experience in a clinical trial led by another investigator, as part of their research and professional development.
Application Due Date(s): August 14, 2020
All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s).
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
https://grants.nih.gov/grants/guide/pa-files/PAR-20-229.html
NIH Exploratory/Developmental Research Grant Program (R21 Parent Grant)
Funding Opportunity Purpose: The NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research.
Application Due Date(s): The first standard application due date for this FOA is June 16, 2020. Standard dates apply.
AIDS Application Due Date(s): The first AIDS application due date for this FOA is September 7, 2020. Standard AIDS dates apply.
All applications are due by 5:00 PM local time of applicant organization. All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Companion Funding Opportunity
PA-20-194, NIH Exploratory/Developmental Research Grant Program (Parent R21, Clinical Trial Required)
PA-20-195, NIH Exploratory/Developmental Research Grant Program (Parent R21, Clinical Trial Not Allowed)
NIH Research Project Grant (Parent R01 Grant)
Research Project Grant (Parent R01 Clinical Trial Not Allowed) and Research Project Grant (Parent R01 Clinical Trial Required)
Funding Opportunity Purpose: The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.
Application Due Date(s): The first application due date for this FOA is June 5, 2020. Standard dates apply.
AIDS Application Due Date(s): The first AIDS application due date for this FOA is September 7, 2020. Standard AIDS dates apply.
All applications are due by 5:00 PM local time of applicant organization. All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on the listed date(s).
International Research in Infectious Diseases, including AIDS (R01), expires: 08/20/2022
Application Due Date(s): July 15, 2020; July 15, 2021; July 15 2022, by 5:00 PM local time of applicant organization.
AIDS Application Due Date(s): August 19, 2020; August 19, 2021; August 19, 2022, by 5:00 PM local time of applicant organization.
This Funding Opportunity Announcement (FOA) encourages applications from organizations/institutions in eligible foreign countries that propose research related to infectious diseases that are of interest/importance to that country.
https://grants.nih.gov/grants/guide/pa-files/PAR-20-108.html
Licensing Opportunity: Improved Antibiotic Therapy of Mycobacterium Tuberculosis
Inhibition of Host Heme Oxygenase-1 as an Adjunctive Treatment to Improve the Outcome of Conventional Antibiotic Chemotherapy of Mycobacterium tuberculosis (Mtb) Infection
This invention describes the adjunctive use of heme oxygenase-1 (HO-1) inhibitors to improve the outcome of conventional antibiotic treatment for tuberculosis. The existent standard of care requires prolonged administration of drug. Due to the long duration of treatment, methods that can more rapidly control tuberculosis in patients are clearly needed.
NIAID researchers have discovered that inhibition of host HO-1 reduces Mycobacterium tuberculosis (Mtb) growth in vivo and, more importantly, when used as an adjunct to conventional chemotherapy, results in a marked improvement in pulmonary bacterial control. In particular, it was found using a mouse model that HO-1 inhibitors enhance bacterial clearance when used in conjunction with conventional antibiotic therapy. Further, no obvious toxic side effects were found. Since this host-directed strategy does not directly target the pathogen itself, it may have an added advantage as a treatment for infections with antibiotic-resistant Mtb strains.
Licensing Contact:
James Robinson,
Email: james.robinson4@nih.gov
Phone: 301-761-7542
More information: https://www.ott.nih.gov/technology/e-174-2016
Myeloid-Derived Suppressor Cells (MDSCs) as Potential Therapeutic Targets in TB/HIV (R01/R21), expires 01/08/2022
Due Dates: January 8, 2020; January 8, 2021; January 10, 2022
The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for support of innovative clinical, preclinical and non-clinical research to determine the potential of MDSCs as a target for host-directed therapeutics for tuberculosis in the context of HIV co-infection, and to better understand the role of host-induced immunosuppression in the progression of Mycobacterium tuberculosis pathogenesis.
R01: https://grants.nih.gov/grants/guide/pa-files/PAR-19-357.html
R21: https://grants.nih.gov/grants/guide/pa-files/par-19-364.html
Doris Duke Charitable Foundation 2019 Clinical Scientist Development Award, due annually in November
Pre-proposals due November 28, 2018
The Clinical Scientist Development Award consists of $150,000 annual direct costs plus $15,000 (10 percent) annual indirect costs for three years. The priority of the CSDA program is to fund outstanding individuals with potential for clinical research careers, whose projects will address highly significant research questions and lead to career advancement. DDCF does not have funding priorities based on disease area or research type.